Collins to industry, top of NIH?

Francis Collins told reporters at a conference call today that he'd be considering "a number of opportunities, some in the private, some in the public sector," and said he'd even consider heading up the NIH, after linkurl:announcing;http://www.the-scientist.com/blog/display/54701/ plans to step down as director of NIH's National Human Genome Research Institute. Collins said that he wouldn't be opposed to taking over the directorship of NIH should that position become available in the next year

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
Francis Collins told reporters at a conference call today that he'd be considering "a number of opportunities, some in the private, some in the public sector," and said he'd even consider heading up the NIH, after linkurl:announcing;http://www.the-scientist.com/blog/display/54701/ plans to step down as director of NIH's National Human Genome Research Institute. Collins said that he wouldn't be opposed to taking over the directorship of NIH should that position become available in the next year or so. "Yeah, I'd be crazy to say, 'I don't think that's anything I want to talk about,'" if the opportunity presented itself, Collins said. But he insisted that his future path is largely uncharted. "I think I may have another career ahead of me," Collins, who is 58 years old, said. "I just don't know what that is." He also said that one of his projects upon leaving NHGRI will be to write a book on the regulatory and scientific issues surrounding linkurl:personalized medicine,;http://www.the-scientist.com/article/display/18849/ which Collins called "a fundamental shift in medical care." Collins said he timed his departure partly to the linkurl:signing;http://www.the-scientist.com/blog/display/54669/ of the Genetic Information Nondiscrimination Act (GINA) into law last week, a major milestone in his career. Collins championed GINA - which became law almost 13 years after being introduced in linkurl:Congress;http://www.the-scientist.com/blog/display/54567/ - during his tenure at NHGRI. "That did have a significant effect on the timing of the decision," Collins said. Collins said that the decision to leave NHGRI was a tough one. "I've been wrestling with this for many months." The only other tidbit that Collins offered as to his recent activities occurred when __Washington Post__ reporter Rick Weiss asked if he had been speaking with anyone from the current presidential campaigns. Collins said that his position at a federal agency constrained him from entering into formal talks of that nature, but did say that he had engaged in "informal and non-specific chatter," without elaborating any further. When I asked Collins about his vision for the future of science policy given the inevitable change of administration this November, he said: "I would hope that there would be a strong and suggestive voice for science in the room, at the table."
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Graphic of amino acid chains folded into proteins

Expi293™ PRO Expression System: Higher Yields Across a Wider Variety of Proteins

Thermo Fisher Logo